- Poster presentation
- Open Access
TiO2 nanoparticles induce cytotoxicity and genotoxicity in human alveolar cells
© Kansara et al; licensee BioMed Central Ltd. 2014
- Published: 21 January 2014
Engineered nanoparticles (ENPs) such as TiO2 are widely used in products such as cosmetics, clothing, food packaging, drug delivery systems, etc. due to their unique physicochemical properties. This has increased the liklihood of ENP exposure in humans. As the ENPs are having small size and high diffusion coefficient, they can migrate rapidly in the air. Therefore, inhalation is considered to be the primary route of exposure to such ENPs. Hence, in the present study an attempt was made to assess the potential toxicological effects of TiO2 NPs in human alveolar cell line (A549).
The average hydrodynamic size, size distribution, zeta potential and stability of TiO2 NPs in DMEM-F12 media were determined by dynamic light scattering (DLS). Internalisaiton of ENPs in cells was detected using flow cytometry. Cytotoxicity was assessed using the MTT and neutral red uptake (NRU) assays. The genotoxic potential of TiO2 NPs was assessed by cytokinesis block micronucleus (CBMN) assay and flow cytometry based assays.
The mean hydrodynamic diameter of TiO2 NPs in DMEM-F12 media, as measured by DLS was 23.27 ± 2.1nm and the zeta potential was -10.1 ± 1 mV. The particles were also found to be stable in the media for upto 72 hr. A significant (p<0.05) concentration dependent uptake of TiO2 NPs was obseverd as evident by an increase in the side scatter (SSC) intensity in flow cytomtery after 6 hr of exposure. A reduction in cell viability was observed as evident by the results of MTT and NRU both as a function of NP concentration as well as time of exposure. Moreover, significant (p<0.05) induction in the micronucleus formation was observed by conventional and flow cytometry based methods at non cytotoxic concentrations.
Our data demonstrate that TiO2 ENPs are internalised in the human alveolar cells and induce cyto- and geno- toxicity. This warrant minimizing the unwanted exposure to the nanotechnology based products and suggests ensuring its safe use both by consumers and industry.
The financial assistance for the Centre for Nanotechnology Research and Applications (CENTRA) by The Gujarat Institute for Chemical Technology (Grant no. ILS/GICT/2013/003) is acknowledged.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.